Welcome to our dedicated page for COLLEGIUM PHARMACEUTICAL SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Collegium Pharmaceutical, Inc. filings document regulatory disclosures for a commercial biopharmaceutical company with ADHD and pain-management medicines. Form 8-K reports cover operating results, earnings presentations, Regulation FD materials, guidance, material agreements, capital-structure matters and clinical or regulatory disclosures tied to the company's product portfolio.
Proxy materials describe shareholder voting matters, board composition, director nominations, board succession, executive compensation and governance practices. The filing record also captures product-related risk disclosures and formal public-company reporting for Collegium's Nasdaq-listed common stock.
PHARMACEUTICAL, INC. reports that Janus Henderson Group plc, through its Asset Managers, beneficially owns 1,825,651 shares of Common Stock, representing 5.8% of the class as reported on 03/31/2026. The filing states the Asset Managers exercise shared voting and dispositive power over those shares and that the Managed Portfolios hold the economic rights to dividends and sale proceeds. The disclosure explains the Asset Managers exercise voting discretion on behalf of client accounts and disclaim direct rights to receive dividends or sale proceeds from the securities held by those accounts.
PHARMACEUTICAL, INC. ownership disclosure: an amended Schedule 13G/A shows Eventide Asset Management, LLC and co‑filers Finny Kuruvilla, M.D., Ph.D. and Robin C. John each report beneficial ownership of 1,424,282 shares, equal to 4.5% of the class.
The filing lists voting and dispositive power allocations: Eventide reports sole voting and dispositive power over 1,424,282 shares, while Kuruvilla and John report shared voting and dispositive power over the same number. The report is signed on 05/15/2026.
PHARMACEUTICAL, INC amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 1,469,449 shares of Common Stock, representing 4.53% of the class.
The filing lists the filers' addresses and confirms sole voting and dispositive power over these shares; signatures dated 05/14/2026.
Collegium Pharmaceutical director Garen G. Bohlin exercised stock options and sold the resulting shares in a same-day transaction. On May 11, 2026, Bohlin exercised options for 8,700 shares of common stock at $16.49 per share, then completed an open-market sale of 8,700 shares at a weighted average price of $37.1829 per share. The sale price reflects multiple trades between $37.18 and $37.43. After these transactions, Bohlin directly holds 62,259 shares of Collegium Pharmaceutical common stock, with the exercised option position reduced to zero.
Collegium Pharmaceutical, Inc. group investors reported shared beneficial ownership positions in Common Stock after briefly exceeding 5% on 05/07/2026. The filing lists Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as filing together under a Joint Filing Agreement.
The cover entries show shared voting power and shared dispositive power of 1,515,406 and 1,519,500 common shares for specific reporting entities, each representing approximately 4.7% of the class in the disclosed rows. The filing states the reporting persons ceased to be beneficial owners of more than 5% by the filing date.
Collegium Pharmaceutical completed its acquisition of AZSTARYS, a CNS stimulant for ADHD, for approximately $650 million in cash, funded with about $350 million of existing cash and a $300 million delayed draw term loan. The deal also includes up to $135 million in milestone payments. Collegium raised its 2026 guidance, now expecting total product revenues, net of $865 to $895 million and adjusted EBITDA of $475 to $500 million, including expected AZSTARYS net revenue of $60 to $70 million for the remainder of 2026 and annual run rate synergies expected to exceed $50 million within twelve months. AZSTARYS generated more than 760,000 prescriptions in 2025 and is supported by six Orange Book-listed patents, most expiring in December 2037. The company also adopted a 2026 Inducement Plan covering up to 325,000 shares for new hires and announced upcoming departures of its Chief Commercial Officer and Chief Medical Officer, both treated as terminations without cause with transition periods.
Invesco Ltd. reports beneficial ownership of 1,591,909 shares of Collegium Pharmaceutical Inc. common stock, representing 5.0% of the class. The filing states Invesco Ltd. has sole voting power for 1,490,397 shares and sole dispositive power for 1,591,909 shares.